- Home
- STEW vs XERS Comparison
STEW vs XERS Comparison
Compare STEW & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | STEW | XERS |
|---|---|---|
| Founded | N/A | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.8B |
| IPO Year | 1996 | 2021 |
Fundamental Metrics
Financial Performance| Metric | STEW | XERS |
|---|---|---|
| Price | $18.96 | $10.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $12.86 |
| AVG Volume (30 Days) | 82.4K | ★ 2.2M |
| Earning Date | 01-01-0001 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 100.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,590,000.00 |
| Revenue This Year | N/A | $32.91 |
| Revenue Next Year | N/A | $23.75 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 142.67 |
| 52 Week Low | $16.55 | $5.25 |
| 52 Week High | $19.05 | $11.42 |
Technical Indicators
Market Signals| Indicator | STEW | XERS |
|---|---|---|
| Relative Strength Index (RSI) | 66.82 | 53.49 |
| Support Level | $18.22 | $9.73 |
| Resistance Level | $18.52 | $10.60 |
| Average True Range (ATR) | 0.17 | 0.47 |
| MACD | 0.07 | -0.09 |
| Stochastic Oscillator | 88.31 | 35.65 |
Price Performance
Historical ComparisonAbout STEW SRH Total Return Fund Inc.
SRH Total Return Fund, Inc. is a non-diversified closed-end management investment company. The company's investment objective is to seek total returns. Its fund utilizes a bottom-up, value-driven investment process to identify securities of good quality businesses trading below estimated intrinsic value. The Funds are available as an actively-managed closed-end fund, an actively managed ETF and a passively-managed ETF.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.